{
    "topic": "coronavirus",
    "source": "Yahoo! The 360",
    "bias": 1,
    "url": "https://news.yahoo.com/is-it-worth-risking-lives-to-speed-up-a-coronavirus-vaccine-195946935.html",
    "title": "Is it worth risking lives to speed up a coronavirus vaccine?",
    "date": "2020-05-05",
    "authors": "Mike Bebernes",
    "content": "\u201c The 360 \u201d shows you diverse perspectives on the day \u2019 s top stories and debates .\nThe Trump administration last week announced a program to dramatically speed up the process of creating a vaccine for the coronavirus through a project called \u201c Operation Warp Speed. \u201d Containment efforts like social distancing and a robust testing regime can help limit virus spread , but experts agree the pandemic won \u2019 t be truly behind us until the broader population is given immunity through a vaccine .\nDespite the urgency , creating a vaccine is a slow , painstaking process . There are as many as 90 vaccines in development around the world , though only a handful are in the earliest stages of human trials . The most optimistic predictions suggest it will be at least a year to 18 months before a vaccine is widely available . That may seem slow , but it would actually shatter the record for fastest vaccine ever developed , which currently stands at four years .\nSome scientists have proposed a controversial step they say could shave months from that time line : deliberately exposing people to the coronavirus to test vaccines more quickly .\nVaccines are typically tested by giving subjects a dose , then letting them go back to their everyday lives with the expectation that a certain number of them will come in contact with the virus . This process could take a long time for the coronavirus , especially given the steps to avoid infection that are part of our typical daily routines . Exposing subjects to the virus \u2014 what \u2019 s known as a \u201c human challenge trial \u201d \u2014 would eliminate that wait time .\nHuman challenge trials are rare because they are seen by many as violating the core principle of medicine : \u201c First , do no harm. \u201d Exposing people to the virus would inevitably mean some of them would get sick or even die .\nProponents of using challenge trials to develop a coronavirus vaccine say the current pandemic challenges that logic . A delay of several months to getting a vaccine on the market would likely lead to thousands of deaths , a far worse outcome than any potential drawbacks of a challenge trial , they argue .\nAdvocates say the health risks to subjects could be dramatically reduced by exposing them to a less potent version of the virus and selecting volunteers from less vulnerable groups , like young adults . A key element is the consent of the people involved in the trial . If individuals are willing to take on the risk of exposure to help save the lives of potentially thousands of people , they should be allowed to do that , supporters say . A website set up to collect names of those willing to participate in a challenge trial has received more than 10,000 volunteers as of Monday .\nThe idea has also received significant pushback from scientists who argue it \u2019 s impossible to gauge how much risk participants are being subjected to because so much is unknown about the virus and how it behaves . There is also skepticism that the results of a challenge trial made up of young , healthy subjects could be applied to the broader population .\nOthers worry about the logistics of carrying out such trials , especially if several vaccines are tested at the same time . Some of those vaccines will inevitably fail , meaning all subjects will be put at risk without any protection . Challenge trials also face unique hurdles \u2014 like determining the correct form and amount of the virus to expose subjects to \u2014 that some experts say could make them take even longer than traditional methods .\nNo challenge trials in the U.S. can be started without the approval of the Food and Drug Administration . A group of 35 lawmakers recently sent a letter to the FDA asking for the agency to acknowledge the urgency of the pandemic and allow future trials to go forward . With only a few vaccines in the early stages of human testing , it will likely be several months before any of them are ready for large-scale trials of any kind .\nThe sooner a vaccine is ready , the more lives will be saved\n\u201c Covid-19 is currently killing thousands of people a day . The vast majority of the world \u2019 s population has no acquired immunity to the disease . And the economy is grinding to a halt to curb its spread . Given the dire situation , the value of even marginally speeding the widespread availability of a vaccine is incredibly high and warrants much more attention and more extreme measures. \u201d \u2014 Matthew Yglesias , Vox",
    "content_original": "\u201cThe 360\u201d shows you diverse perspectives on the day\u2019s top stories and debates.\n\nWhat\u2019s happening\n\nThe Trump administration last week announced a program to dramatically speed up the process of creating a vaccine for the coronavirus through a project called \u201cOperation Warp Speed.\u201d Containment efforts like social distancing and a robust testing regime can help limit virus spread, but experts agree the pandemic won\u2019t be truly behind us until the broader population is given immunity through a vaccine.\n\nDespite the urgency, creating a vaccine is a slow, painstaking process. There are as many as 90 vaccines in development around the world, though only a handful are in the earliest stages of human trials. The most optimistic predictions suggest it will be at least a year to 18 months before a vaccine is widely available. That may seem slow, but it would actually shatter the record for fastest vaccine ever developed, which currently stands at four years.\n\nSome scientists have proposed a controversial step they say could shave months from that time line: deliberately exposing people to the coronavirus to test vaccines more quickly.\n\nVaccines are typically tested by giving subjects a dose, then letting them go back to their everyday lives with the expectation that a certain number of them will come in contact with the virus. This process could take a long time for the coronavirus, especially given the steps to avoid infection that are part of our typical daily routines. Exposing subjects to the virus \u2014 what\u2019s known as a \u201chuman challenge trial\u201d \u2014 would eliminate that wait time.\n\nWhy there\u2019s debate\n\nHuman challenge trials are rare because they are seen by many as violating the core principle of medicine: \u201cFirst, do no harm.\u201d Exposing people to the virus would inevitably mean some of them would get sick or even die.\n\nProponents of using challenge trials to develop a coronavirus vaccine say the current pandemic challenges that logic. A delay of several months to getting a vaccine on the market would likely lead to thousands of deaths, a far worse outcome than any potential drawbacks of a challenge trial, they argue.\n\nAdvocates say the health risks to subjects could be dramatically reduced by exposing them to a less potent version of the virus and selecting volunteers from less vulnerable groups, like young adults. A key element is the consent of the people involved in the trial. If individuals are willing to take on the risk of exposure to help save the lives of potentially thousands of people, they should be allowed to do that, supporters say. A website set up to collect names of those willing to participate in a challenge trial has received more than 10,000 volunteers as of Monday.\n\nThe idea has also received significant pushback from scientists who argue it\u2019s impossible to gauge how much risk participants are being subjected to because so much is unknown about the virus and how it behaves. There is also skepticism that the results of a challenge trial made up of young, healthy subjects could be applied to the broader population.\n\nOthers worry about the logistics of carrying out such trials, especially if several vaccines are tested at the same time. Some of those vaccines will inevitably fail, meaning all subjects will be put at risk without any protection. Challenge trials also face unique hurdles \u2014 like determining the correct form and amount of the virus to expose subjects to \u2014 that some experts say could make them take even longer than traditional methods.\n\nWhat\u2019s next\n\nNo challenge trials in the U.S. can be started without the approval of the Food and Drug Administration. A group of 35 lawmakers recently sent a letter to the FDA asking for the agency to acknowledge the urgency of the pandemic and allow future trials to go forward. With only a few vaccines in the early stages of human testing, it will likely be several months before any of them are ready for large-scale trials of any kind.\n\nPerspectives\n\nSupporters\n\nThe sooner a vaccine is ready, the more lives will be saved\n\n\u201cCovid-19 is currently killing thousands of people a day. The vast majority of the world\u2019s population has no acquired immunity to the disease. And the economy is grinding to a halt to curb its spread. Given the dire situation, the value of even marginally speeding the widespread availability of a vaccine is incredibly high and warrants much more attention and more extreme measures.\u201d \u2014 Matthew Yglesias, Vox",
    "source_url": "www.news.yahoo.com",
    "bias_text": "center",
    "ID": "rhCKt5I9RLpODXHE"
}